How to Use EORTC Bladder Cancer Recurrence & Progression Calculator
The EORTC Bladder Cancer Recurrence & Progression Calculator is a teaching-oriented risk table calculator for non-muscle-invasive bladder cancer factors. The form mirrors the tumor features used in EORTC-style NMIBC risk discussions: number, size, recurrence history, stage, CIS, and grade.
Select tumor count, largest tumor size, prior recurrence category, T stage, carcinoma in situ status, and tumor grade. Use pathology and cystoscopy information from the same clinical episode. If grade or CIS status is pending, the estimate should wait until those results are available.
The panel shows an estimated five-year recurrence percentage plus one-year recurrence, one-year progression, five-year progression, and the point score. Every dropdown represents a categorical risk factor. The calculator assigns points to selected categories and will not invent a value for missing pathology information.
Formula & Theory - EORTC Bladder Cancer Recurrence & Progression Calculator
The EORTC Bladder Cancer Recurrence & Progression Calculator uses this formula or scoring rule:
Risk estimate = Points from tumor number + size + recurrence + T stage + CIS + gradeThis implementation uses an EORTC-style point model for front-end estimation. It is not a substitute for the original tables, pathology review, guideline-based risk groups, or clinician judgment.
Risk tables are population-derived and can be updated by newer guidelines or local practice. Intravesical therapy, re-resection, variant histology, and patient factors may change actual follow-up planning.
Use Cases for EORTC Bladder Cancer Recurrence & Progression Calculator
The EORTC Bladder Cancer Recurrence & Progression Calculator is especially useful for:
- explaining how tumor features affect recurrence risk
- checking educational examples for NMIBC counseling
- comparing low- and high-grade scenario inputs
- preparing questions about follow-up intensity
Use the tool to explain why certain tumor features increase surveillance intensity. It should support, not replace, specialist risk grouping and shared decision-making.